Interest of PET Imagery With 18-FDG in the Extension Assessment of the Cervical Cancer

NCT00199680 | Unknown Phase 2

• 1 other identifier: I03017
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 3

Brief Summary

In cervical cancer prognosis factors are size of the tumour, pelvic and para-aortic lymph nodes involvement. The initial treatment taking is determined by lymph node evaluation. Early stage cervical cancers at their very beginning, with no lymph node involvement, will be treated either by surgery only or by radiotherapy only, or by both at the same time. At advanced stages, from proximal IB to IIB with bad prognosis (tumour larger than 4 cm and pelvic lymph node involvement), as well as for cancers up to distal stages IIB, III and IVA, treatment relies on radio-chemotherapy, either alone or pre-surgery. The pre-therapeutic complete examination of the cervical cancer includes a clinical examination and a pelvic MRI in order to look for pelvic and para-aortic lymph nodes and to precise the volume and the spreading of the tumour in the pelvic area. A meta-analysis estimating the interest of the MRI showed a variable sensitivity and a specificity for the detection of such lymph node metastasis with a sensitivity varying from 24 to 75 % and a specificity between 84 and 100 % according to the studies. As for the use of an 18-FDG PET scan to detect lymph node involvement, the studies realized so far are performed, usually, on a small number of subjects and with heterogeneous populations. However, it seems that such an examination enables a better detection of lymph nodes than the MRI does, especially for para-aortic lymph nodes depending on the studies, sensitivity varies from 57 to 100 %, and specificity between 92 and 100 %. We propose a prospective, multicentric and multidisciplinary study for the estimation of diagnosis methods. The main aim is to estimate the interest of the 18-FDG PET scan for the detection of pelvic and para-aortic lymph node metastasis in patients with cervical cancer, in comparison with the MRI. This study should enable to include 380 patients within 3 years. An 18-FDG scintigraphy will be performed before any treatment together with an MRI. A comparison between the sensitivity and the specificity of both examinations will be established and a correlation with the histology of the lymph node dissection will be made.

Conditions

Cervical Cancer

Keywords

PETscan, cervical cancer

Outcome Measures

Primary Outcomes (1)

• Estimation of the pelvic and/or para-aortic lymph node involvement with the PET, in comparison with the MRI and the histological results of node dissection.

Secondary Outcomes (11)

• Before initial treatment

• - Evaluation of the size and local spreading of the tumour with MRI.

• - Evaluation of tumour fixation with PET (including SUV quantifying).

• - Comparison between both imaging methods.

• Post radio-chemotherapy evaluation

Interventions

PET PROCEDURE

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient with cervical carcinoma: histological proof of epidermoid carcinoma or of adenocarcinoma
• Stage I to IV (limited to pelvic) (FIGO Classification) (see appendix 3)
• Age ≥ 18 years old
• No contra-indication to surgery
• Dated, informed and signed consent from the patient

You may not qualify if:

• Metastatic cervical cancer with extra-pelvic metastasis
• Contra-indication to MRI: implantation of an electronic device, metallic or ferromagnetic foreign body
• Serious co-existing affection with vital prognosis
• Diabetes uncontrolled by a classical treatment: glycaemia \> 1.4g/l
• Pregnancy and lactation
• Uncontrolled infection
• Other cancer within the previous 5 years, except skin basal cell carcinoma, or in situ cervical cancer
• Patient with some deficiency preventing her from completely understanding any requirement of the study, which might compromise the patient's consent and/or the observance of the protocol and the consistent participation to the study.

Sponsors & Collaborators

• University Hospital, Limoges: lead

Study Sites (3)

Gynécologie Obstétrique

Limoges, 87000, France

RECRUITING

Médecine Nucléaire

Limoges, 87000, France

RECRUITING

Oncologie Médicale

Limoges, 87000, France

RECRUITING

Related Publications (1)

• Monteil J, Maubon A, Leobon S, Roux S, Marin B, Renaudie J, Genet D, Fermeaux V, Aubard Y, Tubiana-Mathieu N. Lymph node assessment with (18)F-FDG-PET and MRI in uterine cervical cancer. Anticancer Res. 2011 Nov;31(11):3865-71.

  PMID: 22110211 DERIVED

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Study Officials

• Dominique GENET, MD

  University Hospital, Limoges

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Dominique GENET, MD

CONTACT

+33(0) 555 056 396; dominique.genet@chu-limoges.fr

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 14, 2005
• First Posted: September 20, 2005
• Study Start: October 1, 2003
• Last Updated: February 1, 2006

Record last verified: 2005-09

Locations

FR (3)